Key result
Supplemental D-ribose may improve diastolic function in HFpEF by accelerating ATP synthesis.
Why the study?
Effective treatments specifically for HFpEF are lacking, prompting interest in alternative therapeutic targets such as mitochondrial dysfunction and supplements like D-ribose to improve cardiac bioenergetics.
Does D-ribose supplementation improve mitochondrial function and cardiac performance in patients with HFpEF?
Does D-ribose supplementation improve mitochondrial function and cardiac performance in patients with HFpEF?
This narrative review highlights the potential of D-ribose supplementation to target mitochondrial dysfunction and improve bioenergetics in patients with HFpEF.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for D-ribose in HFpEF; randomized trials required before any clinical adoption.
OBJECTIVE: In this review article, we briefly describe the status of treatment options for HFpEF and the role of mitochondrial dysfunction in the pathogenesis of HFpEF as an alternative therapeutic target. We also examine the mechanisms of D-ribose in cellular energy production and discuss the potential disadvantages and benefits of supplemental use of D-ribose in patients with HFpEF. BACKGROUND: Heart failure is a major cardiovascular disease that impacts over 6 million Americans and is one of the leading causes for morbidity and mortality. Patients with heart failure often experience shortness of breath and fatigue along with impaired physical capacity, all leading to poor quality of life. As a subtype of heart failure, heart failure with preserved ejection fraction (HFpEF) is characterized with impaired diastolic function. Currently, there are no effective treatments specifically for HFpEF, thus clinicians and researchers are searching for therapies to improve cardiac function. Emerging evidence indicate that mitochondrial dysfunction and impaired cardiac bioenergetics are among the underlying mechanisms for HFpEF. There is increased interest in investigating the use of supplements such as D-ribose to enhance mitochondrial function and improve production of adenosine triphosphate (ATP). METHODS: For this narrative review, more than 100 relevant scientific articles were considered from various databases (e.g., PubMed, Web of Science, CINAHL, and Google Scholar) using the keywords "Heart Failure", "HFpEF", "D-ribose", "ATP", "Mitochondria", Bioenergetics", and "Cellular Respiration". CONCLUSIONS: It is essential to find potential targeted therapeutic treatments for HFpEF. Since there is evidence that the HFpEF is related to impaired myocardial bioenergetics, enhancing mitochondrial function could augment cardiac function. Using a supplement such as D-ribose could improve mitochondrial function by increasing ATP and enhancing cardiac performance for patients with HFpEF. There is a recently completed clinical trial with HFpEF patients that indicates D-ribose increases ATP production and improves cardiac ejection fraction.
No takes yet. Share an insight, caveat, or question.
Krueger et al. (2021) conducted a review in Heart failure with preserved ejection fraction (HFpEF). Supplemental D-ribose vs. Placebo or standard therapy was evaluated on Myocardial ATP production and diastolic cardiac function. Supplemental D-ribose may improve mitochondrial bioenergetics by bypassing the oxidative pentose phosphate pathway to accelerate ATP synthesis and enhance diastolic function in HFpEF patients.
Synapse has enriched 10 related papers. Consider them for comparative context: